From GlobeNewswire:

Revolution Medicines, Inc. will have its CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT. The presentation will be available to stream live online and a replay will be accessible for at least 14 days following the conference. Revolution Medicines is a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers. Their R&D pipeline includes RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins and companion inhibitors for use in combination treatment strategies, with several inhibitors currently in clinical development.



Read more: Revolution Medicines to Present at 42nd Annual J.P.